Literature DB >> 16264853

Genomics in breast cancer-therapeutic implications.

Per Eystein Lønning1, Therese Sørlie, Anne-Lise Børresen-Dale.   

Abstract

The introduction of DNA microarray techniques has had dramatic implications on cancer research, allowing researchers to analyze expression of multiple genes in concert and relate the findings to clinical parameters. The main discoveries in breast cancer, as well as in other malignancies, have so far been with respect to two key issues. First, individual tumors arising from the same organ may be grouped into distinct classes based on their gene expression profiles, independent of stage and grade. Second, the biologic relevance of such classification is corroborated by significant prognostic impact. We review how the use of microarray technologies can provide unique possibilities to explore the mechanisms of tumor behavior in vivo that will allow evaluation of prognosis and, potentially, drug resistance. However, in spite of recent advances, we are not yet at a stage where the use of these techniques should be implemented for routine clinical use, whether to define prognostic factors or to predict sensitivity to therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16264853     DOI: 10.1038/ncponc0072

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  18 in total

Review 1.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  A hybrid BPSO-CGA approach for gene selection and classification of microarray data.

Authors:  Li-Yeh Chuang; Cheng-Huei Yang; Jung-Chike Li; Cheng-Hong Yang
Journal:  J Comput Biol       Date:  2011-01-06       Impact factor: 1.479

Review 3.  Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Authors:  Tetyana V Bagnyukova; Ilya G Serebriiskii; Yan Zhou; Elizabeth A Hopper-Borge; Erica A Golemis; Igor Astsaturov
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

4.  Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions.

Authors:  Per E Lønning
Journal:  Ther Adv Med Oncol       Date:  2012-05       Impact factor: 8.168

5.  Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer.

Authors:  Liat Ein-Dor; Or Zuk; Eytan Domany
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

6.  Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology.

Authors:  Jason W Cain; Robert S Hauptschein; Jean K Stewart; Tugba Bagci; Gary G Sahagian; Daniel G Jay
Journal:  Mol Cancer Res       Date:  2011-02-25       Impact factor: 5.852

7.  Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.

Authors:  Luisel Ricks-Santi; J Tyson McDonald; Bert Gold; Michael Dean; Nicole Thompson; Muneer Abbas; Bradford Wilson; Yasmine Kanaan; Tammey J Naab; Georgia Dunston
Journal:  Ethn Dis       Date:  2017-04-20       Impact factor: 1.847

8.  The molecular genetics of breast cancer and targeted therapy.

Authors:  Rachel Suter; James A Marcum
Journal:  Biologics       Date:  2007-09

Review 9.  Prediction of breast cancer metastasis by genomic profiling: where do we stand?

Authors:  Ulrich Pfeffer; Francesco Romeo; Douglas M Noonan; Adriana Albini
Journal:  Clin Exp Metastasis       Date:  2009-03-24       Impact factor: 5.150

10.  Tailored targeted therapy for all: a realistic and worthwhile objective?

Authors:  Per Eystein Lønning
Journal:  Breast Cancer Res       Date:  2009-12-18       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.